You can just call us +1-678-420-5402


News & Events


NEWS

NEW AXESS ONCOLOGY CASES™ SERIES EXPANDED FOR 2016 TO INCLUDE GI, GU, NSCLC, ALL, AND MPN

ATLANTA, GA, July 6, 2016 – Axess Oncology has announced upcoming offerings in their 2016 Oncology CASES™ Report Series. Oncology CASES™ (Community Access via Scientific Engagement Strategies) Reports reveal regional variability in clinical decision making and practice pattern that exist across thirteen unique geographic regions of the US oncology/hematology market place. Here are five upcoming […]

Read More (PDF)


POPULAR AXESS ONCOLOGY CASES™ SERIES’ EXPANDED FOR 2015 TO INCLUDE GASTRIC CANCER, PV, CML, MM, B CELL MALIGNANICES, CLINCAL TRIALS, BIOSIMILARS

ATLANTA (March 5, 2015) – Axess Oncology, an oncology‐focused provider of business intelligence, training, market research and analytics, has announced the initial offerings in their 2015 Oncology CASES™ Report Series’.

Read More (PDF)


DR. STEPHEN SALETAN NAMED AXESS ONCOLOGY MEDICAL DIRECTOR

ATLANTA (November 6, 2014) — Stephen Saletan, M.D., has been named Medical Director for Axess Oncology, Inc., a provider of timely, actionable market research and business intelligence that assesses and predicts movement in the oncology market. Dr. Saletan, a board-certified hematologist-oncologist with a broad background in clinical oncology, academic medicine, pharmaceutical research and medical communications, will enhance Axess core analytics, market research and business intelligence products.

Read More (PDF)


AXESS ONCOLOGY PROJECTS UNINTENDED CONSEQUENCES OF CONTINUED CONSOLIDATION IN US PHYSICIAN MARKETPLACE

ATLANTA (October 27, 2014) – Private medical practices owned by physicians will continue to consolidate at a brisk pace over the next twelve months, according to analysis produced by Axess Oncology, Inc., a provider of timely, actionable market research and business intelligence that predicts and assesses movement in the oncology market. Axess data predict that […]

Read More (PDF)


EVENTS

No events currently available.